Fund Holdings — Decheng Capital LLC

Total Portfolio Value:
$743.41M
Total Bought:
$11.63M
Total Sold:
$63.73M
Net Transaction:
-$52.10M
Securities
▲▼
SharesValue
Q3 2025
▲▼
Q4 2025
▲▼
Change
▲▼
Q3 2025
▲▼
Q4 2025
▲▼
Weight (%)
▲▼
Change
▲▼
CG Oncology, Inc.(CGON)6,371,6696,371,6690$256.65M$264.55M35.59%+$7.90M
Nuvation Bio Inc.(NUVB)25,954,43925,954,4390$96.03M$232.55M31.28%+$136.52M
Upstream Bio, Inc.(UPB)3,285,2933,143,078-142,215$61.80M$85.33M11.48%+$23.54M
Aardvark Therapeutics Inc3,917,2993,917,2990$52.06M$51.41M6.92%-$646.4K
Lyell Immunopharma, Inc.(LYEL)595,466692,050+96,584$9.67M$21.30M2.87%+$11.63M
Newamsterdam Pharma Co Nv
ORDINARY SHARES
657,051592,057-64,994$18.69M$20.77M2.79%+$2.08M
Revolution Medicines, Inc.(RVMD)210,000200,000-10,000$9.81M$15.93M2.14%+$6.12M
Arcus Biosciences, Inc.(RCUS)547,609541,559-6,050$7.45M$12.91M1.74%+$5.46M
Aclaris Therapeutics, Inc.(ACRS)4,041,7364,041,7360$7.68M$12.17M1.64%+$4.49M
Equillium, Inc.(EQ)4,447,3084,447,3080$6.36M$6.89M0.93%+$533.7K
BeyondSpring Inc.SHS(BYSI)4,286,1043,800,702-485,402$7.76M$6.20M0.83%-$1.56M
Crinetics Pharmaceuticals In143,00092,700-50,300$5.96M$4.32M0.58%-$1.64M
Krystal Biotech, Inc.(KRYS)32,30017,300-15,000$5.70M$4.27M0.57%-$1.44M
Aura Biosciences, Inc.(AURA)515,555360,483-155,072$3.19M$1.96M0.26%-$1.22M
Zentalis Pharmaceuticals, Inc.(ZNTL)1,323,3271,323,3270$2.00M$1.79M0.24%-$211.7K
Pyxis Oncology, Inc.(PYXS)326,810326,8100$725.5K$375.8K0.05%-$349.7K
4d Molecular Therapeutics In92,74844,311-48,437$806.0K$332.3K0.04%-$473.6K
Nuvation Bio Inc.WARRANTS(NUVB)646,057646,0570$115.5K$213.2K0.03%+$97.7K
Rezolute, Inc.(RZLT)59,90059,9000$563.1K$141.4K0.02%-$421.7K
GRAIL, Inc.(GRAL)9,6840-9,684$572.6K$0—-$572.6K
Illumina, Inc.(ILMN)7,9790-7,979$757.8K$0—-$757.8K
Moonlake Immunotherapeutics181,6000-181,600$1.30M$0—-$1.30M
Merus Nv186,5460-186,546$17.56M$0—-$17.56M
Page 1 of 1